Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL-HF1: AC01 in Heart Failure With Reduced Ejection Fraction
NCT05642507Phase 2Completed
- Sponsor
- AnaCardio
- Start
- Feb 2023
- Primary completion
- Oct 2025
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of AC01 in heart failure with reduced ejection fraction (HFrEF) (8 arms), sponsored by AnaCardio. Primary endpoints: Adverse Events at 35 days, Vital signs at 28 days and 2 more. Started Feb 2023; status: completed.
02
Drugs
AC01
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05642507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642507.